Novartis withdraws Zometa filings for early-stage breast cancer after negative AZURE result
This article was originally published in Scrip
Executive Summary
Novartis's bone drug Zometa (zoledronic acid) has unexpectedly failed to lower the risk of breast cancer recurrence in the Phase III trial AZURE, which was one of the most highly anticipated oncology drug trials of the year.